Ravi Salgia, MD

Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.

Ravi Salgia, MD, professor and chair, Department of Medical Oncology & Therapeutics Research, associate director for clinical sciences, City of Hope, Durante, California, says there is a difference between precision medicine and personalized medicine.